RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
- Author
- Lisa Depestel (UGent) , Carolina de Carvalho Nunes (UGent) , Liselot Mus (UGent) , Iris Nelen (UGent) , Louis Delhaye (UGent) , Kaylee Keller, Volodimir Olexiouk, Fanny De Vloed (UGent) , Ellen Sanders (UGent) , Aline Eggermont (UGent) , Givani Dewyn, Wouter Van Loocke, Siebe Loontiens (UGent) , Sofia Zanotti (UGent) , Emmy Dolman, Pauline Depuydt, Jolien De Wyn, Bieke Decaesteker (UGent) , Laurentijn Tilleman (UGent) , Filip Van Nieuweburgh, Dieter Deforce (UGent) , Christophe Van Neste, Bram De Wilde (UGent) , Winnok De Vos, Sven Eyckerman (UGent) , Filemon Dela Cruz, Stephen Roberts, Vanessa Vermeirssen (UGent) , Jan Molenaar, Kaat Durinck (UGent) and Franki Speleman (UGent)
- Organization
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8755765
- MLA
- Depestel, Lisa, et al. “RRM2 Enhances MYCN Driven Neuroblastoma Formation and Acts as a Synergistic Target with CHK1 Inhibition.” OncoPoint Symposium 2022, Abstracts, 2022.
- APA
- Depestel, L., de Carvalho Nunes, C., Mus, L., Nelen, I., Delhaye, L., Keller, K., … Speleman, F. (2022). RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. OncoPoint Symposium 2022, Abstracts. Presented at the OncoPoint Symposium 2022, Ghent, Belgium.
- Chicago author-date
- Depestel, Lisa, Carolina de Carvalho Nunes, Liselot Mus, Iris Nelen, Louis Delhaye, Kaylee Keller, Volodimir Olexiouk, et al. 2022. “RRM2 Enhances MYCN Driven Neuroblastoma Formation and Acts as a Synergistic Target with CHK1 Inhibition.” In OncoPoint Symposium 2022, Abstracts.
- Chicago author-date (all authors)
- Depestel, Lisa, Carolina de Carvalho Nunes, Liselot Mus, Iris Nelen, Louis Delhaye, Kaylee Keller, Volodimir Olexiouk, Fanny De Vloed, Ellen Sanders, Aline Eggermont, Givani Dewyn, Wouter Van Loocke, Siebe Loontiens, Sofia Zanotti, Emmy Dolman, Pauline Depuydt, Jolien De Wyn, Bieke Decaesteker, Laurentijn Tilleman, Filip Van Nieuweburgh, Dieter Deforce, Christophe Van Neste, Bram De Wilde, Winnok De Vos, Sven Eyckerman, Filemon Dela Cruz, Stephen Roberts, Vanessa Vermeirssen, Jan Molenaar, Kaat Durinck, and Franki Speleman. 2022. “RRM2 Enhances MYCN Driven Neuroblastoma Formation and Acts as a Synergistic Target with CHK1 Inhibition.” In OncoPoint Symposium 2022, Abstracts.
- Vancouver
- 1.Depestel L, de Carvalho Nunes C, Mus L, Nelen I, Delhaye L, Keller K, et al. RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. In: OncoPoint Symposium 2022, Abstracts. 2022.
- IEEE
- [1]L. Depestel et al., “RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition,” in OncoPoint Symposium 2022, Abstracts, Ghent, Belgium, 2022.
@inproceedings{8755765,
author = {{Depestel, Lisa and de Carvalho Nunes, Carolina and Mus, Liselot and Nelen, Iris and Delhaye, Louis and Keller, Kaylee and Olexiouk, Volodimir and De Vloed, Fanny and Sanders, Ellen and Eggermont, Aline and Dewyn, Givani and Van Loocke, Wouter and Loontiens, Siebe and Zanotti, Sofia and Dolman, Emmy and Depuydt, Pauline and De Wyn, Jolien and Decaesteker, Bieke and Tilleman, Laurentijn and Van Nieuweburgh, Filip and Deforce, Dieter and Van Neste, Christophe and De Wilde, Bram and De Vos, Winnok and Eyckerman, Sven and Dela Cruz, Filemon and Roberts, Stephen and Vermeirssen, Vanessa and Molenaar, Jan and Durinck, Kaat and Speleman, Franki}},
booktitle = {{OncoPoint Symposium 2022, Abstracts}},
language = {{eng}},
location = {{Ghent, Belgium}},
title = {{RRM2 enhances MYCN driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition}},
year = {{2022}},
}